Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the present application.

Listing of Claims:

Claim 1 (previously amended): A compound of structural formula I:



(I)

or a pharmaceutically acceptable salt thereof, wherein;

R^1 is selected from:

(1) C_{1-10}alkyl,

(2) C_{3-10}cycloalkyl,

(3) cycloheteroalkyl,

(4) aryl, and

(5) heteroaryl,

wherein alkyl is optionally substituted with one, two, three or four substituents independently selected from R^a, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are optionally substituted on a carbon or nitrogen atom with one, two, three or four substituents independently selected from R^b;

R^2 is selected from:

(1) C_{3-10}cycloalkyl,

(2) cycloheteroalkyl,

(3) aryl,

(4) heteroaryl,

(5) $-OR^d$,

(6) $-NR^cR^d$, and

(7) $-CO_2R^d$,

wherein each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are optionally substituted on a carbon or nitrogen atom with one, two, three or four substituents independently selected from R^b;

R^3 is C_{1-4}alkyl, wherein alkyl is optionally substituted with one to four substituents independently selected from R^a;

R^6 is selected from:

(1) hydrogen,
(2) C_{1-4}alkyl,
(3) C_{2-4}alkenyl,
(4) C_{2-4}alkynyl,
(5) $-OR^d$,
(6) halogen,
(7) -CN,
(8) $-NR^cR^d$,

wherein alkyl, alkenyl, and alkynyl are optionally substituted with one to four substituents independently selected from R^a

Ar^1 is selected from:

(1) aryl, and
(2) heteroaryl,

each optionally substituted on the carbon or nitrogen with one, two, or three groups independently selected from R^b;

each R^a is independently selected from:

(1) $-OR^c$,
(2) $-NR^cS(O)_mR^d$,
(3) $-NO_2$,
(4) halogen,
(5) $-S(O)_mR^c$,
(6) $-SR^c$,
(7) $-S(O)_2OR^c$,
(8) $-S(O)_mNR^cR^d$,
(9) $-NR^cR^d$,
(10) $-O(CR^eR^f)_nNR^cR^d$,
(11) $-C(O)R^c$,
(12) $-CO_2R^c$,

(13) $-CO_2(CR^eR^f)_nCONR^cR^d$,

(14) $-OC(O)R^c$,

(15) -CN,

(16) $-C(O)NR^cR^d$,

(17) $-NR^cC(O)R^d$,

(18) $-OC(O)NR^cR^d$,

(19) $-NR^cC(O)OR^d$,

(20) $-NR^cC(O)NR^cR^d$,

(21) $-CR^c(N-OR^d)$,

(22) CF_3,

(23) $-OCF_3$,

(24) C_{3-8}cycloalkyl,

(25) cycloheteroalkyl, and

(26) oxo;

each R^b is independently selected from:

(1) R^a,

(2) C_{1-10}alkyl,

(3) C_{3-8}cycloalkyl,

(4) cycloheteroalkyl,

(5) aryl,

(6) arylC_{1-4}alkyl,

(7) heteroaryl, and

(8) heteroarylC_{1-4}alkyl,

wherein alkyl, cycloalkyl, cycloheteroalkyl, and heteroaryl are optionally substituted with oxo, and wherein aryl and heteroaryl are optionally substituted with $-OR^c$, NR^cR^d, or $-C(O)R^c$;

R^c and R^d are independently selected from:

(1) hydrogen,

(2) C_{1-10}alkyl,

(3) C_{2-10} alkenyl,

(4) C_{2-10}alkynyl,

(5) cycloalkyl,

(6) cycloalkyl-C_{1-10}alkyl,

(7) cycloheteroalkyl,

(8) cycloheteroalkyl-C_{1-10} alkyl;

(9) aryl,

(10) heteroaryl,

(11) aryl-C_{1-10}alkyl, and

(12) heteroaryl-C_{1-10}alkyl, or

R^c and R^d together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

or two -OR^c groups together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^h;

R^e and R^f are independently selected from:

(1) hydrogen,

(2) C_{1-10}alkyl,

(3) C_{2-10} alkenyl,

(4) C_{2-10}alkynyl,

(5) cycloalkyl,

(6) cycloalkyl-C_{1-10} alkyl,

(7) cycloheteroalkyl,

(8) cycloheteroalkyl-C_{1-10} alkyl,

(9) aryl,

(10) heteroaryl,

(11) arylC_{1-10} alkyl, and

(12) heteroarylC_{1-10} alkyl, or

R^e and R^f together with the carbon to which they are attached form a ring of 5 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

each Rg is independently selected from

(1) C_{1-10}alkyl,

(2) C_{3-8}cycloalkyl,

(3) cycloheteroalkyl,

(4) aryl,

(5) arylC_{1-4}alkyl,

(6) heteroaryl,

(7) heteroarylC_{1-4}alkyl,

(8) $-S(O)_mR^e$,

(9) $-C(O)R^e$,

(10) $-CO_2R^e$,

(11) $-CO_2(CR^eR^f)_nCONR^eR^f$, and

(12) $-C(O)NR^eR^f$;

each R^h is independently selected from:

(1) C_{1-10}alkyl,

(2) C_{3-8}cycloalkyl,

(3) cycloheteroalkyl,

(4) aryl,

(5) arylC_{1-4}alkyl,

(6) heteroaryl,

(7) heteroarylC_{1-4}alkyl,

(8) $-OR^e$,

(9) $-NR^eS(O)_mR^f$,

(10) $-S(O)_mR^e$,

(11) $-SR^e$,

(12) $-S(O)_2OR^e$,

(13) $-S(O)_mNR^eR^f$,

(14) $-NR^eR^f$,

(15) $-O(CR^eR^f)_nNR^eR^f$,

(16) $-C(O)R^e$,

(17) $-CO_2R^e$,

(18) $-CO_2(CR^eR^f)_nCONR^eR^f$,

(19) $-OC(O)R^e$,

(20) $-CN$,

(21) $-C(O)NR^eR^f$,

(22) $-NR^eC(O)R^f$,

(23) $-OC(O)NR^eR^f$,

(24) $-NR^eC(O)OR^f$,

(25) $-NR^eC(O)NR^eR^f$,

(26) CF_3, and

(27) $-OCF_3$,

m is selected from 1 and 2; and
n is selected from 1, 2, and 3;

provided that when R^1 and R^2 are unsubstituted aryl or unsubstituted heteroaryl, and R^3 is hydrogen or C_{1-4} alkyl, then Ar^1 is substituted with at least one R^b substituent; and

provided that when R^1 is selected from the group consisting of unsubstituted phenyl, *para*-chlorophenyl or *para*–methoxy phenyl, R^2 is unsubstituted phenyl, and R^3 is $-CH_3$, then Ar^1 is not unsubstituted phenyl, *ortho*—CO_2H monosubstituted phenyl, or 3,4-dimethoxy phenyl.

Claim 2 (previously amended): The compound according to Claim 1 wherein:
R^1 is selected from:

(1) C_{1-10}alkyl,
(2) C_{3-10}cycloalkyl,
(3) cycloheteroalkyl,
(4) aryl, and
(5) heteroaryl,

wherein alkyl is optionally substituted with one, two, three or four substituents independently selected from R^a, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

R^2 is selected from:

(1) C_{3-10}cycloalkyl,
(2) cycloheteroalkyl,
(3) aryl,
(4) heteroaryl,
(5) $-OR^d$,
(6) $-NR^cR^d$, and
(7) $-CO_2R^d$,

wherein each cycloalkyl, and cycloheteroalkyl aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

or a pharmaceutically acceptable salt thereof.

Claim 3 (original): The compound according to Claim 2 wherein:

Ar^1 is selected from:

(1) phenyl,
(2) naphthyl,
(3) thienyl,
(4) furanyl,
(5) pyrrolyl,
(6) oxazolyl,
(7) isoxazolyl,
(8) 1,2,5-oxadiazolyl,
(9) 1,2,5-thiadiazolyl,
(10) thiazolyl,
(11) pyrazolyl,
(12) triazolyl,
(13) tetrazolyl,
(14) benzothienyl,
(15) benzofuranyl,
(16) benzoxazolyl,
(17) benzimidazolyl,
(18) benzothiazolyl,
(19) indanyl,
(20) indenyl,
(21) indolyl,
(22) imidazo[1,2-a]pyridinyl,
(23) β-carbolinyl,
(24) 5,6,7,8-tetrahydro-β-carbolinyl,
(25) tetrahydronaphthyl,
(26) 4,5,6,7-tetrahydroindazolyl,
(27) 2,3-dihydrobenzofuranyl,
(28) dihydrobenzopyranyl,
(29) 1,4-benzodioxanyl,
(30) pyridinyl,

(31) pyrimidinyl,
(32) pyrazinyl,
(33) quinolinyl,
(34) isoquinolinyl,
(35) quinazolonyl,
(36) quinazolinyl,
(37) 1,8-naphthyridinyl,
(38) 1,2,3,4-tetrahydro-1,8-naphthyridinyl,
(39) pyrido[3,2-b]pyridinyl,
(40) pyrazolo[2,3-a]pyrimidinyl,
(41) pyrido[1,2-a]pyrimidinyl,
(42) pyrido[1,2-a]pyrimidonyl,
(43) benzopyrimidinyl,
(44) imidazolyl, and
(45) imidazolonyl,

each optionally substituted with one, two, or three groups independently selected from R^b;
or a pharmaceutically acceptable salt thereof.

Claim 4 (original): The compound according to Claim 3 wherein:
R^3 is C_{1-4}alkyl, optionally substituted with one to four substituents independently selected from R^a;
R^6 is selected from:

(1) hydrogen,
(2) methyl,
(3) hydroxyl,
(4) halogen, and
(5) -CN,

wherein methyl is optionally substituted with one to three R^a substituents;
Ar^1 is selected from:

(1) phenyl,
(2) naphthyl,
(3) thienyl,
(4) isoxazolyl,
(5) 1,2,5-oxadiazolyl,

(6) thiazolyl,
(7) pyrazolyl,
(8) triazolyl,
(9) tetrazolyl,
(10) benzofuranyl,
(11) benzoxazolyl,
(12) benzimidazolyl,
(13) benzothiazolyl,
(14) imidazo[1,2-a]pyridinyl,
(15) 5,6,7,8-tetrahydro-β-carbolinyl,
(16) 4,5,6,7-tetrahydroindazolyl,
(17) pyridinyl,
(18) pyrimidinyl,
(19) pyrazinyl,
(20) quinolinyl,
(21) isoquinolinyl,
(22) quinazolonyl,
(23) quinazolinyl,
(24) 1,8-naphthyridinyl,
(25) 1,2,3,4-tetrahydro-1,8-naphthyridinyl,
(26) pyrido[3,2-b]pyridinyl,
(27) pyrazolo[2,3-a]pyrimidinyl,
(28) pyrido[1,2-a]pyrimidinyl,
(29) pyrido[1,2-a]pyrimidonyl,
(30) benzopyrimidinyl,
(31) imidazolyl, and
(32) imidazolonyl,

each optionally substituted with one, two, or three groups independently selected from R^b;

each R^a is independently selected from:

(1) $-OR^c$,
(2) halogen,
(3) $-S(O)_mR^c$,
(4) $-SR^c$,

(5) $-S(O)_2OR^c$,
(6) $-S(O)_mNR^cR^d$,
(7) $-NR^cR^d$,
(8) $-C(O)R^c$,
(9) $-CO_2R^c$,
(10) -CN,
(11) $-C(O)NR^cR^d$,
(12) CF_3,
(13) $-OCF_3$,
(14) C_{3-8}cycloalkyl,
(15) cycloheteroalkyl, and
(16) oxo;

each R^b is independently selected from:

(1) R^a,
(2) C_{1-10}alkyl,
(3) cycloheteroalkyl,
(4) aryl,
(5) arylC_{1-4}alkyl,
(6) heteroaryl, and
(7) heteroarylC_{1-4}alkyl,

wherein alkyl, cycloalkyl, cycloheteroalkyl, heteroaryl are optionally substituted with oxo, and wherein aryl and heteroaryl are optionally substituted with $-OR^c$, NR^cR^d, or $-C(O)R^c$;

R^c and R^d are independently selected from:

(1) hydrogen,
(2) C_{1-10}alkyl,
(3) cycloalkyl,
(4) cycloheteroalkyl,
(5) aryl,
(6) heteroaryl, or

R^c and R^d together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

or two $-OR^c$ groups together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^h;
or a pharmaceutically acceptable salt thereof.

Claim 5 (original): The compound according to Claim 4 wherein:

R^1 and R^2 are independently selected from:

(1) phenyl, and

(2) pyridyl,

each optionally substituted with one to four substituents independently selected from R^b;

R^3 is C_{1-4}alkyl, wherein alkyl is optionally substituted with one to four substituents independently selected from R^a;

R^6 is selected from:

(1) hydrogen,

(2) methyl,

(3) hydroxyl,

(4) halogen, and

(5) –CN;

each R^a is independently selected from:

(1) $-OR^c$,

(2) halogen,

(3) $-S(O)_mR^c$,

(4) $-NR^cR^d$,

(5) $-C(O)R^c$,

(6) $-CO_2R^c$, and

(7) oxo;

or a pharmaceutically acceptable salt thereof.

Claim 6 (original): The compound according to Claim 5 wherein:

R^1 and R^2 are independently selected from:

(1) phenyl,

(2) 4-fluorophenyl,

(3) 2-chlorophenyl,

(4) 3-chlorophenyl,

(5) 4-chlorophenyl,

(6) 4-cyanophenyl,
(7) 4-methylphenyl,
(8) 4-isopropylphenyl,
(9) 4-biphenyl,
(10) 4-bromophenyl,
(11) 4-iodophenyl,
(12) 2,4-dichlorophenyl, and
(13) 2-chloro-4-fluorophenyl;

or a pharmaceutically acceptable salt thereof.

Claim 7 (original): The compound according to Claim 6 wherein:

R^1 and R^2 are independently selected from phenyl and 4-chlorophenyl;

R^3 is methyl, wherein methyl is optionally substituted with one to three substituents independently selected from R^a;

or a pharmaceutically acceptable salt thereof.

Claim 8 (original): A compound selected from:

(1) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzofuran-2-carboxamide;
(2) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-3-chloro-2-naphthamide;
(3) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isoxazole-5-carboxamide;
(4) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrido[3,2-b]pyridine-2-carboxamide;
(5) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazole-3-carboxamide;
(6) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-thiazole-5-carboxamide;
(7) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-nicotinamide;
(8) 2-(1-tetrazolyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(9) 3-(1-tetrazolyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(10) 4-(1-tetrazolyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(11) 5-methyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-thiazole-4-carboxamide;
(12) 2-phenyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(13) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazine-2-carboxamide;
(14) 3-(1-(3,5-dimethyl-pyrazolyl))-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(15) 4-(1-(pyrrolidin-2-one))-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(16) 3-(1-(imidazolidin-2-one))-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

(17) 4-phenyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

(18) 6-bromo-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-picolinamide;

(19) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isonicotinamide;

(20) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-picolinamide;

(21) 4-methyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,2,5-oxadiazole-3-carboxamide;

(22) 3-(1-(pyrrolidin-2-one))-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

(23) 2-bromo-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isonicotinamide;

(24) 3-phenyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

(25) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrimidine-4-carboxamide;

(26) 4-(1-pyrazolyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

(27) 2-(1-pyrazolyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

(28) 5,6,7,8-tetrahydro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-carbazole-3-carboxamide;

(29) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1H-quinazolin-2-one-4-carboxamide;

(30) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzoxazole-2-carboxamide;

(31) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazolo[2,3-a]pyrimidine-6-carboxamide;

(32) 2,4-dimethyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazolo[2,3-a]pyrimidine-6-carboxamide;

(33) 4-(1-piperidinyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

(34) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrimidine-5-carboxamide;

(35) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrido(1,2-a)pyrimidine-4-one-5-carboxamide;

(36) 4,5,6,7-tetrahydro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-indazole-3-carboxamide;

(37) 5-fluoro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzimidazole-2-carboxamide;

(38) 5-phenyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazole-3-carboxamide;

(39) 1,2,3,4-tetrahydro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,8-naphthyridine-7-carboxamide;

(40) 1-methyl-3-ethyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazole-5-carboxamide;

(41) 1-methyl-3-propyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazole-5-carboxamide;

(42) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-quinoline-5-carboxamide;

(43) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-imidazo(1,2-a)pyridine-2-carboxamide;

(44) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-quinoline-4-carboxamide;

(45) 4-bromo-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-nicotinamide;

(46) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isoquinoline-8-carboxamide;

(47) 3-bromo-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-picolinamide;

(48) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isoquinoline-5-carboxamide;

(49) 4-(2-formyl-phenyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(50) 4-(2-hydroxymethyl-phenyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(51) 4-(2-aminophenyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(52) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2(3H)-imidazolone-4-carboxamide;
(53) 3-(1-tetrazolyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isonicotinamide;
(54) 3,4-(ethylenedioxy)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-thiophene-2-carboxamide;
(55) 1-isopropyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-pyrazole-4-carboxamide;
(56) 5-bromo-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-picolinamide;
(57) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,8-naphthyridine-2-carboxamide;
(58) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzothiazole-2-carboxamide;
(59) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzimidazole-2-carboxamide;
(60) 5-chloro-2-(2-(1-pyrrolyl)ethyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(61) 2-(2-phenylethyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(62) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-naphthylene-2-carboxamide;
(63) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-quinoline-5-carboxamide;
(64) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-naphthylene-1-carboxamide;
(65) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(66) 2-chloro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(67) 3-chloro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(68) 4-chloro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(69) 3,5-dichloro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-isonicotinamide;
(70) *N*-[2-(3-pyridyl)-3-(4-chlorophenyl)-1-methylpropyl]-benzamide;
(71) *N*-[2-(2-pyridyl)-3-(4-chlorophenyl)-1-methylpropyl]-benzamide;
(72) *N*-[2-(4-pyridyl)-3-(4-chlorophenyl)-1-methylpropyl]-benzamide; and
(73) *N*-[3-(3-chloro-2-pyridyl)-2-phenyl-1-methylpropyl]-benzamide;

or a pharmaceutically acceptable salt thereof.

Claim 9 (previously amended): A compound of structural formula IA:



(IA)

or a pharmaceutically acceptable salt thereof, wherein;

R^1 is selected from:

(1) aryl, and

(2) heteroaryl,

wherein aryl and heteroaryl are optionally substituted on the carbon or nitrogen with one to four substituents independently selected from R^b;

R^2 is selected from:

(1) aryl, and

(2) heteroaryl,

wherein aryl and heteroaryl are optionally substituted on the carbon or nitrogen with one to four substituents independently selected from R^b;

R^3 is C_{1-4}alkyl,

wherein alkyl is optionally substituted with one to four substituents independently selected from R^a;

Ar^1 is selected from:

(1) aryl, and

(2) heteroaryl,

each optionally substituted on the carbon or nitrogen with one, two, or three groups independently selected from R^b;

each R^a is independently selected from:

(1) $-OR^c$,

(2) $-NR^cS(O)_mR^d$,

(3) $-NO_2$,

(4) halogen,

(5) $-S(O)_mR^c$,

(6) $-SR^c$,

(7) $-S(O)_2OR^c$,

(8) $-S(O)_mNR^cR^d$,

(9) $-NR^cR^d$,

(10) $-O(CR^eR^f)_nNR^cR^d$,

(11) $-C(O)R^c$,

(12) $-CO_2R^c$,

(13) $-CO_2(CR^eR^f)_nCONR^cR^d$,

(14) $-OC(O)R^c$,

(15) -CN,

(16) $-C(O)NR^cR^d$,

(17) $-NR^cC(O)R^d$,

(18) $-OC(O)NR^cR^d$,

(19) $-NR^cC(O)OR^d$,

(20) $-NR^cC(O)NR^cR^d$,

(21) $-CR^c(N-OR^d)$,

(22) CF_3,

(23) $-OCF_3$,

(24) C_{3-8}cycloalkyl,

(25) cycloheteroalkyl, and

(26) oxo;

each R^b is independently selected from:

(1) R^a,

(2) C_{1-10}alkyl,

(3) C_{3-8}cycloalkyl,

(4) cycloheteroalkyl,

(5) aryl,

(6) arylC_{1-4}alkyl,

(7) heteroaryl, and

(8) heteroarylC_{1-4}alkyl,

wherein alkyl, cycloalkyl, cycloheteroalkyl, and heteroaryl are optionally substituted with oxo, and wherein aryl and heteroaryl are optionally substituted with $-OR^c$, NR^cR^d, or $-C(O)R^c$;

R^c and R^d are independently selected from:

(1) hydrogen,

(2) C_{1-10}alkyl,

(3) C_{2-10} alkenyl,

(4) C_{2-10}alkynyl,

(5) cycloalkyl,

(6) cycloalkyl-C_{1-10}alkyl,

(7) cycloheteroalkyl,

(8) cycloheteroalkyl-C_{1-10} alkyl;

(9) aryl,

(10) heteroaryl,

(11) aryl-C_{1-10}alkyl, and

(12) heteroaryl-C_{1-10}alkyl, or

R^c and R^d together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

or two -OR^c groups together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^h;

R^e and R^f are independently selected from:

(1) hydrogen,

(2) C_{1-10}alkyl,

(3) C_{2-10} alkenyl,

(4) C_{2-10}alkynyl,

(5) cycloalkyl,

(6) cycloalkyl-C_{1-10} alkyl,

(7) cycloheteroalkyl,

(8) cycloheteroalkyl-C_{1-10} alkyl,

(9) aryl,

(10) heteroaryl,

(11) arylC_{1-10} alkyl, and

(12) heteroarylC_{1-10} alkyl, or

R^e and R^f together with the carbon to which they are attached form a ring of 5 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

each Rg is independently selected from

(1) C_{1-10}alkyl,

(2) C_{3-8}cycloalkyl,

(3) cycloheteroalkyl,

(4) aryl,

(5) arylC_{1-4}alkyl,

(6) heteroaryl,

(7) heteroarylC_{1-4}alkyl,

(8) $-S(O)_mR^e$,

(9) $-C(O)R^e$,

(10) $-CO_2R^e$,

(11) $-CO_2(CR^eR^f)_nCONR^eR^f$, and

(12) $-C(O)NR^eR^f$;

each R^h is independently selected from:

(1) C_{1-10}alkyl,

(2) C_{3-8}cycloalkyl,

(3) cycloheteroalkyl,

(4) aryl,

(5) arylC_{1-4}alkyl,

(6) heteroaryl,

(7) heteroarylC_{1-4}alkyl,

(8) $-OR^e$,

(9) $-NR^eS(O)_mR^f$,

(10) $-S(O)_mR^e$,

(11) $-SR^e$,

(12) $-S(O)_2OR^e$,

(13) $-S(O)_mNR^eR^f$,

(14) $-NR^eR^f$,

(15) $-O(CR^eR^f)_nNR^eR^f$,

(16) $-C(O)R^e$,

(17) $-CO_2R^e$,

(18) $-CO_2(CR^eR^f)_nCONR^eR^f$,

(19) $-OC(O)R^e$,

(20) $-CN$,

(21) $-C(O)NR^eR^f$,

(22) $-NR^eC(O)R^f$,

(23) $-OC(O)NR^eR^f$,

(24) $-NR^eC(O)OR^f$,

(25) $-NR^eC(O)NR^eR^f$,

(26) CF_3, and

(27) $-OCF_3$,

m is selected from 1 and 2; and
n is selected from 1, 2, and 3;

provided that when R^1 and R^2 are unsubstituted aryl or unsubstituted heteroaryl, and R^3 is ~~hydrogen or~~ C 1-4 alkyl, Ar^1 is substituted with at least one R^b substituent; and

provided that when R^1 is selected from the group consisting of unsubstituted phenyl, *para*-chlorophenyl or *para*–methoxy phenyl, R^2 is unsubstituted phenyl, and R^3 is $-CH_3$, Ar^1 is not unsubstituted phenyl, *ortho*—CO_2H monosubstituted phenyl, or 3,4-dimethoxy phenyl.

Claim 10 (original): The compound according to Claim 9 wherein:
R^1 and R^2 are independently selected from:

(1) phenyl,
(2) naphthyl, and
(3) pyridyl,

each optionally substituted with one to four substituents independently selected from R^b;
or a pharmaceutically acceptable salt thereof.

Claim 11 (Original): The compound according to Claim 10 wherein:
Ar^1 is selected from:

(1) phenyl,
(2) naphthyl,
(3) thienyl,
(4) furanyl,
(5) pyrrolyl,
(6) oxazolyl,
(7) isoxazolyl,
(8) 1,2,5-oxadiazolyl,
(9) 1,2,5-thiadiazolyl,
(10) thiazolyl,
(11) pyrazolyl,
(12) triazolyl,
(13) tetrazolyl,

(14) benzothienyl,
(15) benzofuranyl,
(16) benzoxazolyl,
(17) benzimidazolyl,
(18) benzothiazolyl,
(19) indanyl,
(20) indenyl,
(21) indolyl,
(22) imidazo[1,2-a]pyridinyl,
(23) β-carbolinyl,
(24) 5,6,7,8-tetrahydro-β-carbolinyl,
(25) tetrahydronaphthyl,
(26) 4,5,6,7-tetrahydroindazolyl,
(27) 2,3-dihydrobenzofuranyl,
(28) dihydrobenzopyranyl,
(29) 1,4-benzodioxanyl,
(30) pyridinyl,
(31) pyrimidinyl,
(32) pyrazinyl,
(33) quinolinyl,
(34) isoquinolinyl,
(35) quinazolonyl,
(36) quinazolinyl,
(37) 1,8-naphthyridinyl,
(38) 1,2,3,4-tetrahydro-1,8-naphthyridinyl,
(39) pyrido[3,2-b]pyridinyl,
(40) pyrazolo[2,3-a]pyrimidinyl,
(41) pyrido[1,2-a]pyrimidinyl,
(42) pyrido[1,2-a]pyrimidonyl,
(43) benzopyrimidinyl,
(44) imidazolyl, and
(45) imidazolonyl,

each optionally substituted with one, two, or three groups independently selected from R^b;

or a pharmaceutically acceptable salt thereof.

Claim 12 (previously amended): The compound of claim 11 wherein:
R^3 is C_{1-4}alkyl,
wherein alkyl is optionally substituted with one to four substituents independently selected from R^a;
Ar^1 is selected from:

(1) phenyl,
(2) naphthyl,
(3) thienyl,
(4) isoxazolyl,
(5) 1,2,5-oxadiazolyl,
(6) thiazolyl,
(7) pyrazolyl,
(8) triazolyl,
(9) tetrazolyl,
(10) benzofuranyl,
(11) benzoxazolyl,
(12) benzimidazolyl,
(13) benzothiazolyl,
(14) imidazo[1,2-a]pyridinyl,
(15) 5,6,7,8-tetrahydro-β-carbolinyl,
(16) 4,5,6,7-tetrahydroindazolyl,
(17) pyridinyl,
(18) pyrimidinyl,
(19) pyrazinyl,
(20) quinolinyl,
(21) isoquinolinyl,
(22) quinazolonyl,
(23) quinazolinyl,
(24) 1,8-naphthyridinyl,
(25) 1,2,3,4-tetrahydro-1,8-naphthyridinyl,
(26) pyrido[3,2-b]pyridinyl,
(27) pyrazolo[2,3-a]pyrimidinyl,

(28) pyrido[1,2-a]pyrimidinyl,

(29) pyrido[1,2-a]pyrimidonyl,

(30) benzopyrimidinyl,

(31) imidazolyl, and

(32) imidazolonyl,

each optionally substituted with one, two, or three groups independently selected from R^b;

each R^a is independently selected from:

(1) $-OR^c$,

(2) halogen,

(3) $-S(O)_mR^c$,

(4) $-SR^c$,

(5) $-S(O)_2OR^c$,

(6) $-S(O)_mNR^cR^d$,

(7) $-NR^cR^d$,

(8) $-C(O)R^c$,

(9) $-CO_2R^c$,

(10) -CN,

(11) $-C(O)NR^cR^d$,

(12) CF_3,

(13) $-OCF_3$,

(14) C_{3-8}cycloalkyl,

(15) cycloheteroalkyl, and

(16) oxo;

each R^b is independently selected from:

(1) R^a,

(2) C_{1-10}alkyl,

(3) cycloheteroalkyl,

(4) aryl,

(5) arylC_{1-4}alkyl,

(6) heteroaryl, and

(7) heteroarylC_{1-4}alkyl,

wherein alkyl, cycloalkyl, cycloheteroalkyl, heteroaryl are optionally substituted with oxo, and wherein aryl and heteroaryl are optionally substituted with $-OR^c$, NR^cR^d, or $-C(O)R^c$;

R^c and R^d are independently selected from:

(1) hydrogen,
(2) C_{1-10}alkyl,
(3) cycloalkyl,
(4) cycloheteroalkyl,
(5) aryl,
(6) heteroaryl, or

R^c and R^d together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,
or two -OR^c groups together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,
each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^h;
or a pharmaceutically acceptable salt thereof.

Claim 13 (original): The compound according to Claim 12, wherein:
R^1 and R^2 are independently selected from:

(1) phenyl, and
(2) pyridyl,

each optionally substituted with one to four substituents independently selected from R^b;
R^3 is C_{1-4}alkyl, wherein alkyl is optionally substituted with one to four substituents independently selected from R^a;
each R^a is independently selected from:

(1) -OR^c,
(2) halogen,
(3) -$S(O)_mR^c$,
(4) -NR^cR^d,
(5) -$C(O)R^c$,
(6) -CO_2R^c, and
(7) oxo;

or a pharmaceutically acceptable salt thereof.

Claim 14 (original): The compound according to Claim 13, wherein:
R^1 and R^2 are independently selected from:

(1) phenyl,
(2) 4-fluorophenyl,
(3) 2-chlorophenyl,
(4) 3-chlorophenyl,
(5) 4-chlorophenyl,
(6) 4-cyanophenyl,
(7) 4-methylphenyl,
(8) 4-isopropylphenyl,
(9) 4-biphenyl,
(10) 4-bromophenyl,
(11) 4-iodophenyl,
(12) 2,4-dichlorophenyl, and
(13) 2-chloro-4-fluorophenyl;
or a pharmaceutically acceptable salt thereof.

Claim 15 (original): The compound according to Claim 14 wherein:
R^1 and R^2 are independently selected from phenyl and 4-chlorophenyl;
R^3 is methyl, wherein methyl is optionally substituted with one to three substituents independently selected from R^a;
or a pharmaceutically acceptable salt thereof.

Claim 16 (original): A composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.

Claim 17 (original): A composition comprising a compound according to Claim 8 and a pharmaceutically acceptable carrier.

Claim 18 (original): A method of preventing obesity in a person at risk for obesity comprising administration to said person of about 0.001 to about 100 mg/kg of a compound according to Claim 1.

Claim 19 (original): A method of preventing obesity in a person at risk for obesity comprising administration to said person of about 0.001 to about 100 mg/kg of a compound according to Claim 8.

Claim 20 (original): A method of treating a disease mediated by the Cannabinoid-1 receptor comprising administration of a therapeutically effective amount of a compound of Claim 1 to a patient in need of such treatment.

Claim 21 (original): The method according to Claim 20 wherein the disease mediated by the Cannabinoid-1 receptor is selected from: psychosis, memory deficit, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, schizophrenia, substance abuse disorders, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, asthma, obesity, and other eating disorders associated with excessive food intake.

Claim 22 (original): The method according to Claim 21 wherein the disease mediated by the Cannabinoid-1 receptor is an eating disorder associated with excessive food intake.

Claim 23 (original): The method according to Claim 22 wherein the eating disorder asssociated with excessive food intake is selected from obesity, bulimia nervosa, and compulsive eating disorders.

Claim 24 (original): The method according to Claim 23 wherein the eating disorder associated with excessive food intake is obesity.

Claims 25-30 (cancelled).